Swiss contract development and manufacturing organization (CDMO) Lonza (VTX: LONN) has signed a long-term commercial supply ...

Vertex Pharmaceuticals received marketing authorization from Health Canada for its treatment of sickle cell disease.

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...

Basel, Switzerland, 24 September 2024 – Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today the signature of a long-term commercial supply ...

Epigenetic drugs induce heritable modifications to genetic material that result in changes in gene expression without ...

Editas Medicine made significant progress in advancing reni-cel, despite a 65% drop in stock price. Click here to read why ...

at 15:50 Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent ...

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked ...

The California Academy of Family Physicians (CAFP) expresses deep disappointment today following Governor Gavin Newsom's veto of AB 2250 (Weber). The bill, authored by Assemblymember Akilah Weber, MD, ...

After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a ...

Children ages 12 and older with sickle cell are now eligible for a newly FDA-approved treatment through the MACC Fund Center ...